Company Overview
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of biologic agents to enhance the outcomes in patients with immunologically-driven disorders. The company is based in Redwood City, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.22.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -76.11% |
| 6 Months: | -45.85% |
| 3 Months: | +51.58% |
| 1 Month: | -0.08% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)49.79 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 77.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | JSPR Jasper Therapeutics, Inc. PHARMA | 0.71 | -0.76 | $23.62M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -228.67K | -327.56K | -6.01M | -6.25M | -8.42M | -10.08M | -12.78M | -11.96M | -12.71M | -13.95M | -17.83M | -19.36M | -15.07M | -15.99M | -19.89M | -21.80M | -27.08M | -19.17M | -10.95M |
| Net Income | 1.43M | -3.43M | -201.19K | -9.75M | -8.41M | -3.41M | -2.21M | -10.40M | -11.86M | -14.26M | -16.08M | -17.54M | -13.73M | -14.58M | -18.64M | -21.24M | -26.72M | -18.74M | -1.17M |
| Diluted EPS | - | - | - | - | - | -0.69 | -0.06 | -0.29 | -0.32 | -1.62 | -1.47 | -1.60 | -1.03 | -0.97 | -1.24 | -1.41 | -1.74 | -1.13 | -0.04 |
| R&D Expense | - | - | 4.52M | 4.42M | 5.16M | 7.19M | 8.19M | 8.13M | 9.02M | 9.80M | 13.30M | 14.85M | 10.30M | 11.30M | 14.46M | 16.16M | 21.20M | 14.39M | 5.81M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -20.68M | -36.83M | -51.20M | -68.86M | -76.24M | -83.88M |
| Net Income | -31.67M | -30.64M | -37.69M | -64.47M | -71.27M | -75.80M |
| Diluted EPS | - | -2.69 | -10.33 | -6.18 | -4.89 | -3.95 |
| R&D Expense | 15.88M | 25.42M | 34.63M | 51.78M | 55.82M | 63.10M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | 101.69M | 23.36M | 93.65M | 48.36M | 94.89M | 79.90M | 35.78M |
| Total Equity | -4.73M | -35.13M | 69.52M | 35.99M | 78.44M | 61.67M | 4.15M |
| Cash & Equivalents | 1.21M | 19.84M | 84.70M | 38.25M | 86.89M | 71.64M | 28.69M |
| Total Liabilities | 3.61M | 14.65M | 24.14M | 12.37M | 16.45M | 18.23M | 31.63M |
| Current Liabilities | 111.36K | 4.01M | 8.02M | 7.07M | 12.37M | 15.24M | 13.20M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -18.27M | -33.68M | -45.86M | -52.07M | -62.60M | -77.16M |
| Investing Cash Flow | 198.34K | -2.43M | -576.00K | -267.00K | -532.00K | 5.00K |
| Financing Cash Flow | 11.29M | 100.97M | 55.00K | 100.97M | 47.88M | 34.21M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 90.1% | -44.1% | -104.7% | -82.2% | -115.6% | -1,826.1% |
| ROCE % | -106.9% | -43.0% | -124.0% | -83.4% | -117.9% | -371.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Velan Capital Investment Management LP | 16.04% | 5.34M | $3.30M |
| 2 | Acorn Capital Advisors, LLC | 8.64% | 2.88M | $1.78M |
| 3 | Kingdon Capital Management LLC | 8.13% | 2.70M | $1.67M |
| 4 | Vanguard Capital Management LLC | 7.04% | 2.34M | $1.45M |
| 5 | Rock Springs Capital Management, LP | 6.62% | 2.20M | $1.36M |
| 6 | Carlyle Group Inc. | 6.41% | 2.13M | $1.32M |
| 7 | GSA Capital Partners LLP | 3.21% | 1.07M | $660.67K |
| 8 | Millennium Management Llc | 2.93% | 973.87K | $601.65K |
| 9 | Lion Point Capital, LP | 2.79% | 930.00K | $574.55K |
| 10 | Geode Capital Management, LLC | 1.59% | 527.62K | $325.96K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for JSPR
Jasper Therapeutics beats Q2 expectations but shares fall after results
Jasper Therapeutics Inc. (NASDAQ:JSPR) reported better-than-expected second-quarter 2026 results on Monday, although shares of the clinical-stage biotechnology company fell 4.
Jasper gets a lifeline in merger with immune drugmaker Kira
The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from setbacks that have wiped out most of its market value.
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to addr…
Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7
Jasper Therapeutics, Inc. (NASDAQ:JSPR) is one of the 8 Most Oversold Penny Stocks to Buy Right Now. On April 1, 2026, Evercore ISI lowered the price target on Jasper Therapeutics, Inc. (NASDAQ:JSPR) to $7 from $12 and maintained an Outperf…
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to ad…
Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight
Recently published Chronic Spontaneous Urticaria Market Insights report includes a comprehensive understanding of current treatment practices, chronic spontaneous urticaria emerging drugs, market share of individual therapies, and current a…
JSPR — Frequently Asked Questions
What is the current share price of Jasper Therapeutics, Inc. (JSPR)?
As of 2026-09-19 21:16 PDT, Jasper Therapeutics, Inc. (JSPR) trades at $0.71 on NasdaqCM. Its 52-week range is $0.34 to $3.11.
What is the market capitalisation of JSPR?
Jasper Therapeutics, Inc. (JSPR) has a market capitalisation of $23.62M on NasdaqCM.
What is the P/E ratio of JSPR?
JSPR trades at a trailing price-to-earnings (P/E) ratio of -0.76. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 12.36.
Is JSPR a good stock to buy?
This page provides a data-driven analysis of Jasper Therapeutics, Inc. (JSPR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.